Cargando…

Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms

Dyslipidemia, steatohepatitis and insulin resistance are among the components of metabolic syndrome (MS). Nutraceuticals containing chitosan, beta-sitosterol and/or ferulic acid and their nanostructures could have a potential role for management of MS. The aim of the present study was to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Okbi, Sahar Y., Ali, Ola, Aly, A. S., Refaat, D., Esmail, Reham S. H., Elbakry, Hagar F. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374579/
https://www.ncbi.nlm.nih.gov/pubmed/37500657
http://dx.doi.org/10.1038/s41598-023-38837-9
_version_ 1785078803728433152
author Al-Okbi, Sahar Y.
Ali, Ola
Aly, A. S.
Refaat, D.
Esmail, Reham S. H.
Elbakry, Hagar F. H.
author_facet Al-Okbi, Sahar Y.
Ali, Ola
Aly, A. S.
Refaat, D.
Esmail, Reham S. H.
Elbakry, Hagar F. H.
author_sort Al-Okbi, Sahar Y.
collection PubMed
description Dyslipidemia, steatohepatitis and insulin resistance are among the components of metabolic syndrome (MS). Nutraceuticals containing chitosan, beta-sitosterol and/or ferulic acid and their nanostructures could have a potential role for management of MS. The aim of the present study was to assess the efficacy of the aforementioned nutraceuticals in treatment of MS in rat and their interaction with atorvastatin, a hypolipidemic drug. The two nutraceuticals and their nanostructures were prepared and the nanostructures were assessed by transmission electron microscope and Fourier-Transform Infra-red Spectrometry. MS was induced in rats by feeding high fructose-high fat diet (HFFD). Different groups of rats fed HFFD and treated with the different nutraceuticals, atorvastatin and atorvastatin in combination with different nutraceuticals, control fed on balanced diet and control consumed HFFD without treatments were run. Plasma glucose, lipid profile, aminotransferases activity, total antioxidant capacity, malondialdehyde, urea, creatinine, insulin, high sensitivity C-reactive protein, and adiponectin were assessed along with calculation of insulin resistance. Liver fat and histopathology were investigated. All nutraceuticals in original and nanostructures showed beneficial effects in the treatment of MS, superiority was ascribed to nutraceuticals composed of chitosan and ferulic acid in both forms. A more promising treatment of MS belonged to atorvastatin administered with the different nutraceuticals.
format Online
Article
Text
id pubmed-10374579
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103745792023-07-29 Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms Al-Okbi, Sahar Y. Ali, Ola Aly, A. S. Refaat, D. Esmail, Reham S. H. Elbakry, Hagar F. H. Sci Rep Article Dyslipidemia, steatohepatitis and insulin resistance are among the components of metabolic syndrome (MS). Nutraceuticals containing chitosan, beta-sitosterol and/or ferulic acid and their nanostructures could have a potential role for management of MS. The aim of the present study was to assess the efficacy of the aforementioned nutraceuticals in treatment of MS in rat and their interaction with atorvastatin, a hypolipidemic drug. The two nutraceuticals and their nanostructures were prepared and the nanostructures were assessed by transmission electron microscope and Fourier-Transform Infra-red Spectrometry. MS was induced in rats by feeding high fructose-high fat diet (HFFD). Different groups of rats fed HFFD and treated with the different nutraceuticals, atorvastatin and atorvastatin in combination with different nutraceuticals, control fed on balanced diet and control consumed HFFD without treatments were run. Plasma glucose, lipid profile, aminotransferases activity, total antioxidant capacity, malondialdehyde, urea, creatinine, insulin, high sensitivity C-reactive protein, and adiponectin were assessed along with calculation of insulin resistance. Liver fat and histopathology were investigated. All nutraceuticals in original and nanostructures showed beneficial effects in the treatment of MS, superiority was ascribed to nutraceuticals composed of chitosan and ferulic acid in both forms. A more promising treatment of MS belonged to atorvastatin administered with the different nutraceuticals. Nature Publishing Group UK 2023-07-27 /pmc/articles/PMC10374579/ /pubmed/37500657 http://dx.doi.org/10.1038/s41598-023-38837-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Al-Okbi, Sahar Y.
Ali, Ola
Aly, A. S.
Refaat, D.
Esmail, Reham S. H.
Elbakry, Hagar F. H.
Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms
title Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms
title_full Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms
title_fullStr Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms
title_full_unstemmed Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms
title_short Management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms
title_sort management of metabolic syndrome by nutraceuticals prepared from chitosan and ferulic acid with or without beta-sitosterol and their nanoforms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374579/
https://www.ncbi.nlm.nih.gov/pubmed/37500657
http://dx.doi.org/10.1038/s41598-023-38837-9
work_keys_str_mv AT alokbisahary managementofmetabolicsyndromebynutraceuticalspreparedfromchitosanandferulicacidwithorwithoutbetasitosterolandtheirnanoforms
AT aliola managementofmetabolicsyndromebynutraceuticalspreparedfromchitosanandferulicacidwithorwithoutbetasitosterolandtheirnanoforms
AT alyas managementofmetabolicsyndromebynutraceuticalspreparedfromchitosanandferulicacidwithorwithoutbetasitosterolandtheirnanoforms
AT refaatd managementofmetabolicsyndromebynutraceuticalspreparedfromchitosanandferulicacidwithorwithoutbetasitosterolandtheirnanoforms
AT esmailrehamsh managementofmetabolicsyndromebynutraceuticalspreparedfromchitosanandferulicacidwithorwithoutbetasitosterolandtheirnanoforms
AT elbakryhagarfh managementofmetabolicsyndromebynutraceuticalspreparedfromchitosanandferulicacidwithorwithoutbetasitosterolandtheirnanoforms